Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:GTHP OTCMKTS:MICR NASDAQ:STRR OTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTHPGuided Therapeutics$0.25-12.5%$0.26$0.06▼$0.32$23.41M0.412,112 shs420 shsMICRMicron Solutions$0.00$0.00$0.00▼$0.56N/A0.440 shsN/ASTRRStar Equity$11.23+1.1%$6.74$8.26▼$15.90$30.61M0.423,643 shs16,810 shsVASOVaso$0.12-3.8%$0.12$0.11▼$0.18$21.06M1.39126,181 shs101,761 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTHPGuided Therapeutics0.00%+17.01%+2.19%+7.69%+115.22%MICRMicron Solutions0.00%0.00%0.00%+100.00%-99.23%STRRStar Equity0.00%-5.93%+18.57%+466.84%+177.75%VASOVaso0.00%-3.17%-3.81%-6.21%-35.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTHPGuided Therapeutics$0.25-12.5%$0.26$0.06▼$0.32$23.41M0.412,112 shs420 shsMICRMicron Solutions$0.00$0.00$0.00▼$0.56N/A0.440 shsN/ASTRRStar Equity$11.23+1.1%$6.74$8.26▼$15.90$30.61M0.423,643 shs16,810 shsVASOVaso$0.12-3.8%$0.12$0.11▼$0.18$21.06M1.39126,181 shs101,761 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTHPGuided Therapeutics0.00%+17.01%+2.19%+7.69%+115.22%MICRMicron Solutions0.00%0.00%0.00%+100.00%-99.23%STRRStar Equity0.00%-5.93%+18.57%+466.84%+177.75%VASOVaso0.00%-3.17%-3.81%-6.21%-35.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGTHPGuided Therapeutics 0.00N/AN/AN/AMICRMicron Solutions 0.00N/AN/AN/ASTRRStar Equity 1.50Reduce$5.00-55.48% DownsideVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GTHP, MICR, STRR, and VASO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025STRRStar EquityWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025STRRStar EquityWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/14/2025STRRStar EquityMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGTHPGuided Therapeutics$10K2,048.20N/AN/A($0.12) per share-2.04MICRMicron Solutions$22.57M0.00N/AN/AN/A∞STRRStar Equity$140.06M0.22N/AN/A$14.80 per share0.76VASOVaso$86.77M0.23$0.01 per share11.85$0.16 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGTHPGuided Therapeutics-$2.42M-$0.050.00∞N/AN/AN/A-219.85%11/12/2025 (Estimated)MICRMicron Solutions-$1.29M-$0.430.00∞N/AN/AN/AN/AN/ASTRRStar Equity-$4.77M-$1.300.00N/AN/A-2.81%-3.81%-2.84%11/18/2025 (Estimated)VASOVaso$950K-$0.01N/A∞N/A-0.35%-1.14%-0.38%11/12/2025 (Estimated)Latest GTHP, MICR, STRR, and VASO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GTHPGuided TherapeuticsN/A-$0.01N/A-$0.01N/A$0.12 million8/13/2025Q2 2025STRRStar Equity-$0.26$1.86+$2.12$1.07$16.75 million$23.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGTHPGuided TherapeuticsN/AN/AN/AN/AN/AMICRMicron SolutionsN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGTHPGuided TherapeuticsN/A0.130.03MICRMicron SolutionsN/AN/AN/ASTRRStar EquityN/A3.043.04VASOVasoN/A1.511.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGTHPGuided Therapeutics9.69%MICRMicron SolutionsN/ASTRRStar Equity3.84%VASOVasoN/AInsider OwnershipCompanyInsider OwnershipGTHPGuided Therapeutics66.83%MICRMicron Solutions26.10%STRRStar Equity10.40%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGTHPGuided Therapeutics583.60 million27.73 millionNot OptionableMICRMicron Solutions1103.75 million2.77 millionNot OptionableSTRRStar Equity1,3002.76 million2.47 millionNot OptionableVASOVaso260175.75 million97.54 millionNot OptionableGTHP, MICR, STRR, and VASO HeadlinesRecent News About These CompaniesSmall Business: Turning grief into art with handcrafted urn business VasoOctober 12 at 1:19 PM | nzherald.co.nzNBlood-Based Protein Biomarkers Linked to Acute Pain in Sickle Cell DiseaseOctober 10 at 2:26 AM | clinicalpainadvisor.comCHigh-Resolution 7-Tesla MRI Reveals Brain Microvessel Pulsations Linked to Aging: StudyOctober 8, 2025 | medicaldialogues.inMIndividuals with sickle cell disease face long delays to pain care in emergency departmentOctober 8, 2025 | msn.comGene-Edited Cells Alleviate Pain Crisis in Sickle Cell DiseaseSeptember 18, 2025 | medscape.comMTelescope Innovations Appoints Vaso Vlachos as Chief Operating OfficerSeptember 2, 2025 | finance.yahoo.comBKFC Budva live results: Vaso Bakocevic faces Wilhelm OttAugust 30, 2025 | fightmag.comFVASO Central Bank Of India IFSC Code, KHEDAAugust 26, 2025 | moneycontrol.comVaso Stock Down Following Q2 Earnings as Revenue and Margins FallAugust 21, 2025 | zacks.comPfizer Provides Update on Phase 3 Inclacumab Study for the Treatment of People with Sickle Cell DiseaseAugust 19, 2025 | pipelinereview.comPInclacumab Misses Endpoint In Sickle Cell Disease TrialAugust 19, 2025 | empr.comEPfizer's sickle cell drug fails late-stage trialAugust 15, 2025 | msn.comPfizer's sickle-cell treatment efforts falter as drug fails studyAugust 15, 2025 | msn.comVaso Corporation reports Q2 revenue $20M vs. $20.2M last yearAugust 14, 2025 | msn.comVaso Corporation Announces Financial Results for Second Quarter of 2025August 14, 2025 | finance.yahoo.comVaso Corporation Announces Financial Results for Second Quarter of 2025 | VASO Stock NewsAugust 14, 2025 | gurufocus.comFirst Patient Dosed In Clinical Trial Of Therapy For Sickle DiseaseAugust 8, 2025 | msn.comGreece stuns USA to reach women’s water polo World Championship finalJuly 23, 2025 | neoskosmos.comNLevel of physical activity tied to less pain, blood viscosity in SCD: StudyJune 26, 2025 | sicklecellanemianews.comSCorn in a Cup (Elote en Vaso)June 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy Wall Street Is Betting Billions on Oklo's Nuclear VisionBy Jeffrey Neal Johnson | September 26, 2025Is Super Micro Next in Line for a Big AI Takeover?By Gabriel Osorio-Mazilli | September 23, 2025Azure Leads While AI Excitement Fuels Microsoft StockBy Chris Markoch | September 19, 20253 AI Infrastructure Stocks With Upside After the Summer RallyBy Chris Markoch | September 18, 2025Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming SoonBy Thomas Hughes | September 25, 2025GTHP, MICR, STRR, and VASO Company DescriptionsGuided Therapeutics OTCMKTS:GTHP$0.25 -0.04 (-12.50%) As of 12:07 PM EasternGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Micron Solutions OTCMKTS:MICR$0.0002 0.00 (0.00%) As of 10/10/2025Micron Solutions, Inc. operates as a contract manufacturer for the medical device, defense, and life sciences markets. It offers precision machining, thermoplastic injection molding, mold making products; sensors; orthopedic implants and devices; and diagnostic test kits. The company provides solutions for medical, orthopedics, consumer, and automotive industries. Micron Solutions, Inc. was founded in 1978 and is based in Fitchburg, Massachusetts.Star Equity NASDAQ:STRR$11.23 +0.12 (+1.08%) Closing price 03:57 PM EasternExtended Trading$11.20 -0.03 (-0.22%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.Vaso OTCMKTS:VASO$0.12 0.00 (-3.76%) As of 03:55 PM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
